Case Study: Ofatumumab-Induced Remission in Refractory Panuveitis Accompanied by Multiple Sclerosis - Takeaways - MDSpire

Case Study: Ofatumumab-Induced Remission in Refractory Panuveitis Accompanied by Multiple Sclerosis

  • By

  • Agni M. Konitsioti

  • Jeany Q. Lammert

  • Sabine Vay

  • Gereon R. Fink

  • Michael Schroeter

  • Clemens Warnke

  • April 29, 2026

  • 0 min

Share

  • 1

    Ofatumumab, a B-cell–depleting monoclonal antibody, induced sustained remission in a patient with refractory panuveitis and multiple sclerosis.

  • 2

    The patient had a long history of severe non-infectious panuveitis, which failed to respond to conventional immunosuppressive therapies and biologics.

  • 3

    B cells play a significant role in the pathogenesis of non-infectious uveitis, suggesting B-cell–targeted therapies may be effective for refractory cases.

  • 4

    Uveitis is a major cause of visual impairment, affecting young adults and often linked to autoimmune conditions like multiple sclerosis.

  • 5

    Current treatment options for non-infectious uveitis include corticosteroids, immunosuppressants, and biologics, with ongoing research into B-cell therapies.

Original Source(s)

Case Study: Ofatumumab-Induced Remission in Refractory Panuveitis Accompanied by Multiple Sclerosis

  • by Agni M. Konitsioti, Jeany Q. Lammert, Sabine Vay, Gereon R. Fink, Michael Schroeter, Clemens Warnke

  • April 29, 2026

Related Content

Targeting IL-6 in the Treatment of Uveitic Macular Edema

Vamikibart shows promise as a new treatment for uveitic macular edema, improving vision and safety compared to existing steroids. Source: Dr. Rahul Khurana.

Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized

Vamikibart Shows Early Safety in Uveitic Macular Edema

Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven